aTyr Pharma Investor Presentation — August 2020

Document content

NON -CONFIDENTIALDelivering the Potential of Immunotherapy

NON -CONFIDENTIAL NON -CONFIDENTIALLegal Disclaimer

This presentation and the accompanying oral commentary contain forward -looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than

statements of historical facts contained in this presentation and the accompanying oral commentary, including statements rega rding our future results of operations or financial condition, business

strategy and plans and objectives of management for future operations, are forward -looking statements. In some cases, you can id entify forward -looking statements because they contain words such

as ‘‘anticipate,’’ ‘‘believe,’’ ‘‘contemplate,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘pl an,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ ‘‘will’’ or ‘‘would’’ or the negative of

these words or other similar terms or expressions, although not all forward -looking statements contain these words. These forwar d-looking statements include, but are not limited to, statements

concerning the following: the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug and other regulatory

submissions; the initiation, timing, progress and results of collaborations and partnerships; our expectations regarding the activity of our product candidate ATRC -101 or potential future product

candidates once administered in a human subject; our ability to identify and develop product candidates for treatment of addi tional disease indications; our or a potential future collaborator’s ability to

obtain and maintain regulatory approval of any of our current or potential future product candidates; our expectations regard ingthe achievement and timing of research, development and regulatory